Efficacy of Different Treatment Regimens for Antiphospholipid Syndrome-related Recurrent Spontaneous Abortion

Background: Antiphospholipid syndrome (APS)-related immune factors are considered as an important cause of recurrent spontaneous abortion (RSA). Anticoagulant and anti-inflammatory treatments are believed to effectively improve adverse pregnancy outcomes by affecting the abnormal autoimmune response of the maternal-fetal interface. The aim of this study was to observe the clinical characteristics and treatment outcomes of anticoagulant regimens and anti-inflammatory plus anticoagulation regimens for APS-related RSA. Methods: APS-related RSA cases from September 2011 to September 2016 at Peking University Third Hospital were retrospectively analyzed. The patients were assigned to study group (anti-inflammation plus anticoagulation) and control group (simple anticoagulation). The incidence of repeat abortion, the incidence of placental dysfunction, the gestational weeks of pregnancy, and the mean weight of the fetus were observed. Results: The pregnancy and neonatal outcome indicators of the repeat pregnancy loss rate (11.11% vs. 22.70%), placental dysfunction-related diseases (6.35% vs. 15.60%), the mean birth weight of infants born after 24 weeks gestation (3152.41 ± 844.67 g vs. 2765.76 ± 816.40 g), full-term delivery weight (3456.28 ± 419.79 g vs. 3076.18 ± 518.79 g), the proportions of low birth weight infants (12.70% vs. 21.98%), and small for gestational age (6.35% vs. 14.18%) differed significantly between the study and control groups (all P < 0.05). The incidence of preterm delivery, term delivery, and stillbirth was not significantly different between the two groups, and there was no significant difference between the study and control groups in gestational age at birth (37.6 ± 3.3 weeks vs. 36.9 ± 3.2 weeks; P > 0.05). Conclusion: The anti-inflammatory and anticoagulation regimen is more effective than the simple anticoagulation regimen in the treatment of APS recurrent abortion.

[1]  K. Sunassee,et al.  Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome. , 2016, Journal of autoimmunity.

[2]  C. Gordon,et al.  BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. , 2016, Rheumatology.

[3]  C. Gordon,et al.  BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. , 2016, Rheumatology.

[4]  E. Schleußner,et al.  Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. , 2015, Annals of internal medicine.

[5]  N. Costedoat-Chalumeau,et al.  Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome? , 2015, Autoimmunity reviews.

[6]  A. Barton,et al.  Economics of Stratified Medicine in Rheumatoid Arthritis , 2014, Current Rheumatology Reports.

[7]  T. Porter,et al.  14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. , 2014, Autoimmunity reviews.

[8]  Nahid Qushmaq,et al.  Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety , 2014, ISRN rheumatology.

[9]  R. Levy,et al.  Pregnancy Morbidity in Antiphospholipid Syndrome: What Is the Impact of Treatment? , 2014, Current Rheumatology Reports.

[10]  P. Cacoub,et al.  Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. , 2013, Autoimmunity reviews.

[11]  Gynecologists Practice Bulletin No. 132: Antiphospholipid syndrome. , 2012, Obstetrics and gynecology.

[12]  L. Carbillon,et al.  Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels. , 2012, Journal of reproductive immunology.

[13]  G. Sordo,et al.  Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome , 2012, Lupus.

[14]  S. le Cessie,et al.  Classical complement activation as a footprint for murine and human antiphospholipid antibody‐induced fetal loss , 2011, The Journal of pathology.

[15]  M. Khamashta,et al.  First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. , 2011, Blood.

[16]  Y. Ioannou,et al.  Domain I of β2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome , 2010, Lupus.

[17]  A. Gilman‐Sachs,et al.  REVIEW ARTICLE: Immunological Modes of Pregnancy Loss , 2010, American journal of reproductive immunology.

[18]  M. Vilardell‐Tarrés,et al.  Is Obstetric Antiphospholipid Syndrome a Primary Nonthrombotic, Proinflammatory, Complement-Mediated Disorder Related to Antiphospholipid Antibodies? , 2010, Obstetrical & gynecological survey.

[19]  P. D. de Groot,et al.  Pathogenic role of antiphospholipid antibodies , 2008, Lupus.

[20]  Definitions of infertility and recurrent pregnancy loss. , 2008, Fertility and sterility.

[21]  D. Kirchhofer,et al.  Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. , 2007, Blood.

[22]  J. Lambris,et al.  Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. , 2003, The Journal of clinical investigation.

[23]  D. Vinatier,et al.  Antiphospholipid syndrome and recurrent miscarriages. , 2001, European journal of obstetrics, gynecology, and reproductive biology.

[24]  H. Cohen,et al.  High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. , 1995, Human reproduction.

[25]  H. Cohen,et al.  Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. , 1995, Human reproduction.